


Claims:

1. (currently amended) A compound having the formula



or a pharmaceutically acceptable salt thereof,

wherein

$\text{R}^1$  is  $-\text{C}_4\text{-C}_6\text{-alkyl}$ , aryl,  $-\text{C}_3\text{-C}_7$  cycloalkyl or 3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo,  $-\text{C}_1\text{-C}_6$  alkyl,  $-\text{O}-(\text{C}_1\text{-C}_6$  alkyl), -OH, -CN, -COOR', -OC(O)R', NHR', N(R')<sub>2</sub>, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted  $-\text{C}_1\text{-C}_6$  alkyl, with the proviso that when n is 2,  $\text{R}^1$  cannot be  $-\text{C}_3\text{-C}_7$  cycloalkyl or 3- to 10-membered heterocycle,

m is an integer ranging from 1-10; and

n is an integer ranging from 1-10.

2. (original) The compound of claim 1 wherein  $\text{R}^1$  is phenyl.

3. (original) The compound of claim 1 wherein n is an integer ranging from 1-5.

4. (original) The compound of claim 1 wherein m is 2.

5. (original) The compound of claim 1 wherein  $\text{R}^1$  is phenyl, m is 2 and n is 3.

6. (original) The compound of claim 1 wherein  $\text{R}^1$  is  $-4\text{-N}(\text{CH}_3)_2\text{-phenyl}$  and m is 1.

7. (original) The compound of claim 1 wherein  $\text{R}^1$  is  $-4\text{-N}(\text{CH}_3)_2\text{-phenyl}$ , m is 1 and n is 4.


8. (original) The compound of claim 1 wherein  $\text{R}^1$  is  $-4\text{-N}(\text{CH}_3)_2\text{-phenyl}$ , m is 1 and n is 5.

Claims 9 - 31 (canceled)

32. (original) A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or vehicle.

Claims 33 - 40 (canceled)

**41. (currently amended)** A method for increasing the sensitivity of a cancer cell to the cytotoxic effects of radiotherapy, said method comprising contacting said cell with a compound having the formula:



(Ia)

or a pharmaceutically acceptable salt thereof,

wherein

$\text{R}^{1a'}$  is  $-\text{C}_4\text{-C}_6$  alkyl, aryl,  $-\text{C}_3\text{-C}_7$  cycloalkyl or 3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo,  $-\text{C}_1\text{-C}_6$  alkyl,  $-\text{O}-(\text{C}_1\text{-C}_6$  alkyl), -OH, -CN, -COOR',  $-\text{OC}(\text{O})\text{R}'$ , NHR',  $\text{N}(\text{R}')_2$ ,  $-\text{NHC}(\text{O})\text{R}'$  or  $-\text{C}(\text{O})\text{NHR}'$  groups wherein R' is -H or unsubstituted  $-\text{C}_1\text{-C}_6$  alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10,

in an amount sufficient to increase the sensitivity of said cell to the cytotoxic effects of radiotherapy.

Claims 42-49 (canceled)

**50. (currrently amended)** The method of any one of claims 41-49 claim 41 wherein the cell is an *in vivo* cell.

**51. (original)** A method for treating cancer, said method comprising administering to a subject in need thereof the compound or a pharmaceutically acceptable salt of the compound of claim 1 in an amount sufficient to treat said cancer.

Claims 52-59 (canceled)

**60. (currrently amended)** The method of any one of claims 51-59 claim 51 wherein the subject is a human.


61. (currently amended) The method of ~~any one of claims 51-59~~ claim 51 wherein the cancer is Non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, larynx cancer, cervical cancer, nasopharynx cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophageal cancer, rectal cancer, small-cell lung cancer, non-small cell lung cancer, brain cancer, or a CNS neoplasm.

62. (currently amended) The method of ~~any one of claims 51-59~~ claim 51 further comprising administering to said subject another therapeutic agent or a pharmaceutically acceptable salt thereof.

63. (original) The method of claim 62 wherein the other therapeutic agent is an anticancer agent.

64. (currently amended) A method for treating cancer, said method comprising:

(a) administering to a subject in need thereof, a compound having the formula:



(Ia)

or a pharmaceutically acceptable salt thereof,

wherein

$\text{R}^{1a'}$  is  $-\text{C}_1\text{-}\text{C}_6$  alkyl, aryl,  $-\text{C}_3\text{-}\text{C}_7$  cycloalkyl or 3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo,  $-\text{C}_1\text{-}\text{C}_6$  alkyl,  $-\text{O}-(\text{C}_1\text{-}\text{C}_6 \text{ alkyl})$ , -OH, -CN, -COOR', -OC(O)R', NHR', N(R')<sub>2</sub>, -NHC(O)R' or -C(O)NHR' groups wherein R' is -H or unsubstituted  $-\text{C}_1\text{-}\text{C}_6$  alkyl;

m is an integer ranging from 0-10; and

n is an integer ranging from 1-10,

in an amount sufficient to sensitize a cancer cell to the cytotoxic effects of radiotherapy; and

(b) administering to said subject an amount of radiotherapy sufficient to treat said cancer.

Claims 65 - 72 (canceled)

**73. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 wherein the compound administered in step (a) and the radiotherapy administered in step (b) act adjunctively.

**74. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 wherein the subject is a human.

**75. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 wherein the cancer is Non-Hodgkin's lymphoma, Hodgkin's disease, Ewing's sarcoma, testicular cancer, prostate cancer, larynx cancer, cervical cancer, nasopharynx cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, esophageal cancer, rectal cancer, small-cell lung cancer, non-small cell lung cancer, brain cancer, or a CNS neoplasm.

**76. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 further comprising administering to said subject another therapeutic agent or a pharmaceutically acceptable salt thereof.


**77. (currently amended)** The method of claim 76 wherein the other therapeutic agent is an anticancer agent.

**78. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 wherein the administering of step (a) is done prior to the administering of step (b).

**79. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 wherein the administering of step (a) is done subsequent to the administering of step (b).

**80. (currently amended)** The method of ~~any one of claims 64-72~~ claim 64 wherein the administering of step (a) and the administering of step (b) are done concurrently.

**81. (currently amended)** A method for treating a neurological disease, said method comprising administering to a subject in need thereof a compound having the formula



(Ia)

or a pharmaceutically acceptable salt thereof,

wherein

$R^{1a}$  is  $-C_4-C_6\text{-alkyl}$ , aryl,  $-C_3-C_7$  cycloalkyl or 3- to 10-membered heterocycle, any of which may be unsubstituted or substituted with one or more of the following groups: -halo,  $-C_1-C_6$  alkyl,  $-O-(C_1-C_6\text{ alkyl})$ ,  $-OH$ ,  $-CN$ ,  $-COOR'$ ,  $-OC(O)R'$ ,  $NHR'$ ,  $N(R')_2$ ,  $-NHC(O)R'$  or  $-C(O)NHR'$  groups wherein  $R'$  is  $-H$  or unsubstituted  $-C_1-C_6$  alkyl;

$m$  is an integer ranging from 0-10; and

$n$  is an integer ranging from 1-10,

in an amount sufficient to treat said neurological disease.

Claims 82 - 89 (**canceled**)

90. **(currently amended)** The method of ~~any one of claims 81-89~~ claim 81 wherein said disease of the central nervous system is Huntington's disease, lupus, or schizophrenia.

91. **(currently amended)** The method of ~~any one of claims 81-89~~ claim 81 wherein the subject is a human.